The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Open accessAbstract
BACKGROUND: Patients with hemophilia A rely on exogenous factor VIII to prevent bleeding in joints, soft tissue, and the central nervous system. Although successful gene transfer has been reported in patients with hemophilia B, the large size of the factor VIII coding region has precluded improved outcomes with gene therapy in patients with hemophilia A. METHODS: We infused a single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with severe hemophilia A. Participants were enrolled sequentially into one of three dose cohorts (low dose [one participant], intermediate dose [one participant], and high dose [seven participants]) and were followed through 52 weeks. RESULTS: Factor VIII activity levels remained at 3 IU or less per deciliter in the recipients of the low or intermediate dose. In the high-dose cohort, the factor VIII activity level was more than 5 IU per deciliter between weeks 2 and 9 after gene transfer in all seven participants, and the level in six participants increased to a normal value (>50 IU per deciliter) that was maintained at 1 year after receipt of the dose. In the high-dose cohort, the median annualized bleeding rate among participants who had previously received prophylactic therapy decreased from 16 events before the study to 1 event after gene transfer, and factor VIII use for participant-reported bleeding ceased in all the participants in this cohort by week 22. The primary adverse event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper limit of the normal range or less. Progression of preexisting chronic arthropathy in one participant was the only serious adverse event. No neutralizing antibodies to factor VIII were detected. CONCLUSIONS: The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stabilization of hemostasis and a profound reduction in factor VIII use in all seven participants. In this small study, no safety events were noted, but no safety conclusions can be drawn. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795 ; EudraCT number, 2014-003880-38 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both transgene products, FVIII-SQ and FIX-R338L, demonstrate variable activity measurements in OSA versus chromogenic assay (CSA) determinants of factor activity that are reproducible across trials.144,145,149,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [28]
In the citing paper
“clinical gene therapy using a codon-optimized exogenous construct to compensate for mutations in a nuclear gene (e.g. hemophilia, [69]) is ongoing”
From Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinás, A. M., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,949
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H. Z., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 682
Flagged first, then by citations
Research works printed but not linked: 1
- Falese L, Gene Ther
Cited by
Sorted by citations
Items 501–600 of 692
Mitochondrial Targeting Probes, Drug Conjugates, and Gene Therapeutics
Cerrato, C. P., Kivijärvi, T., & Langel, Ü. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1752-6_27 · Cited by 4
Agarwal, S., Hermans, C. R. J. R., Miesbach, W., Peyvandi, F., Sidonio, R. F., Osmond, D., Newman, V., Henshaw, J., & Pipe, S. W. (2024) · Haemophilia · doi:10.1111/hae.15025 · Cited by 4
Liver health in hemophilia in the era of gene therapy
Dargaud, Y. G., Levrero, M., Bailly, F., Lienhart, A., & Zoulim, F. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109064 · Cited by 4
A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency
Levy‐Mendelovich, S., Avishai, E., Samelson‐Jones, B. J., Dardik, R., Brutman‐Barazani, T., Nisgav, Y., Livnat, T., & Kenet, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910336 · Cited by 5
Quon, D. V. K., Wang, J., Wang, M., Pepperell, D., Park, Y. S., Kenet, G., Mahlangu, J. N., Khoo, T., Robinson, T. M., Chavele, K.-M., et al. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241304645 · Cited by 4
Pei, X., Han, M., & Zhang, L. (2019) · Blood Science · doi:10.1097/bs9.0000000000000030 · Cited by 4
HemPHL: A Personal Health Library and mHealth Recommender to Promote Self-Management of Hemophilia
Olusanya, O. A., Ammar, N., Brakefield, W. S., Crescioni, M., Chupka, J., Tarver, D., & Shaban‐Nejad, A. (2021) · Studies in health technology and informatics · doi:10.3233/shti210231 · Cited by 4
Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A
Zhao, M., Sun, Y., Yin, M., Zhao, J.-J., Li, S.-A., Li, G., Zhang, F., Xu, J., Meng, F., Zhang, B., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.145 · Cited by 4
Hémophilie : la thérapie génique, enfin…
Jordan, B. (2018) · médecine/sciences · doi:10.1051/medsci/20183403016 · Cited by 4
rFVIIIFC for hemophilia A prophylaxis
Mahlangu, J. N. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1549478 · Cited by 4
Hemophilia – Impact of Recent Advances on Management
Puthenveetil, G., & Nugent, D. J. (2019) · The Indian Journal of Pediatrics · doi:10.1007/s12098-019-03062-8 · Cited by 4
Gene and cell therapy in South Africa: Current status and future prospects
Ely, A., Bloom, K., Maepa, M. B., Mahlangu, J. N., Pepper, M. S., & Arbuthnot, P. B. (2019) · South African Medical Journal · doi:10.7196/samj.2019.v109i8b.13819 · Cited by 4
Larsen, M. S., Juul, R. V., Zintner, S. M., Kristensen, A. T., Margaritis, P., Kjelgaard-Hansen, M. J., Wiinberg, B., Simonsson, U. S. H., & Kreilgaard, M. (2019) · Haemophilia · doi:10.1111/hae.13899 · Cited by 4
Brunetti‐Pierri, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817344-2.00030-7 · Cited by 4
Noda, M., Tatsumi, K., Matsui, H., Matsunari, Y., SATO, T. A., Fukuoka, Y., Hotta, A., Okano, T., Kichikawa, K., Sugimoto, M., et al. (2021) · Regenerative Therapy · doi:10.1016/j.reth.2021.08.009 · Cited by 4
Shao, W., Sun, J., Chen, X., Dobbins, A. L., Merricks, E. P., Samulski, R. J., Nichols, T. C., & Li, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.815317 · Cited by 4
Croteau, S. E. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.009 · Cited by 4
Cushing, M. M., Kelley, J. M., Klapper, E. B., Friedman, D. F., Goel, R., Heddle, N. M., Hopkins, C. K., Karp, J. K., Pagano, M. B., Perumbeti, A., et al. (2018) · Transfusion · doi:10.1111/trf.14520 · Cited by 4
Functional identification of factor VIII B domain regions in hepatocyte cells
Zhang, J., Ming-ming, L., Qian-qing, Z., Yun-hong, W., Chong-yang, Z., & Li, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.132 · Cited by 4
Sawczuk, I. S., & Wechsler, M. E. (1985) · PubMed Central · Cited by 4
Adeno‐associated Viral Vectors in Gene Therapy
Ling, C., Zhong, L., & Srivastava, A. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0005738.pub3 · Cited by 6
Current progress and future direction in the treatment for hemophilia
Shima, M. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02786-9 · Cited by 4
The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes
Simini, G., & Batty, P. A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.028 · Cited by 3
Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep
Taghian, T., Gallagher, J., Bertrand, S., Baker, W. C., Mercado, K. R. L., Benatti, H. R., Hall, E. F., Lopez, Y., McElroy, A. W., McCarthy, J. T., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci182942 · Cited by 3
The biology of congenital urinary bladder outflow obstruction
Roberts, N. A., Chan, M., & Woolf, A. S. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.09.009 · Cited by 4
Kashiwakura, Y., Nakajima, Y., Horinaka, K., Lopes, T. J. S., Furuta, Y., Yamaguchi, Y., Baatartsogt, N., Hayakawa, M., Katakai, Y., Uchiyama, S., et al. (2026) · Blood · doi:10.1182/blood.2025028481 · Cited by 3
Matino, D., Ligia, S., Nazy, I., Kwok, S., Moffat, K. A., Carlino, S. A., & Iorio, A. (2025) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2026.100170 · Cited by 3
Immunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 3
Fong, S., Swystun, L. L., Batty, P. A., & Lillicrap, D. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207251406537 · Cited by 3
Lawton, S., Manson, M. A., Fan, M., Chao, T.-Y., Chen, C., Kim, P., Campbell, C., Cai, X., Kooi, A. V., & Miao, C. H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.010 · Cited by 3
Ismail, A. M., Witt, E., Bouwman, T., Clark, W. T., Yates, B., Franco, M., & Fong, S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101294 · Cited by 3
Circadian Clock Gene Bmal1: A Molecular Bridge from AKI to CKD
Yang, S., Ye, Z., Chen, L., Zhou, X., Li, W., & Fan, C. (2025) · Biomolecules · doi:10.3390/biom15010077 · Cited by 3
Nordahl, K. M. L., Larsen, M. S., Zintner, S. M., Small, J. C., Kjelgaard-Hansen, M. J., Häger, M., Petersen, M., Wiinberg, B., & Margaritis, P. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14804 · Cited by 3
Gene Therapy in Hemophilia: Latest Developments
Sanchez-Lara, P. A., Nathanson, J., & Valentino, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-93990-8_18 · Cited by 3
Elnaggar, M., Al-Mohannadi, A., Hasan, W., Abdelrahman, D., Al-Kubaisi, M. J., Pavlovski, I., Gentilcore, G., Sathappan, A., Kizhakayil, D., Ali, A. I., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022009014 · Cited by 3
Casinghino, S. R., Tartaro, K. R., Anderson, J., Ravindra, K. C., Lee, S., Qian, J., Schneider, P. A., Virgen‐Slane, R., Whiteley, L. O., & Lanz, T. A. (2025) · Journal of Immunotoxicology · doi:10.1080/1547691x.2025.2459931 · Cited by 3
Noncoding RNAs in Cardiovascular Disease
Lesizza, P., Paldino, A., Merlo, M., Giacca, M., & Sinagra, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00003-4 · Cited by 3
Requirements to participate in haemophilia clinical trials
Mahlangu, J. N. (2020) · Haemophilia · doi:10.1111/hae.13886 · Cited by 3
Hemşinlioğlu, C., Aslan, E. S., Taştan, C., Çakırsoy, D., Turan, R. D., Seyis, U., Elek, M., Karakuş, G. S., Günaydın, Ö. S., Abanuz, S., et al. (2023) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2023.2022.0318 · Cited by 3
Ectopic expression of factor VIII in MSCs and hepatocytes derived from rDNA targeted hESCs
Sun, Q., Liu, X., Wu, Y. C., Niu, W., Long, P., Liu, J., Lei, M., Hu, Y., Wu, L., Li, Z., et al. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.08.007 · Cited by 3
[Research progress of gene therapy in clinical application].
Chen, X., Chen, L., & Li, D. (2019) · PubMed · doi:10.13345/j.cjb.190363 · Cited by 3
Gene-produced FVIII: measure for measure
Ragni, M. V. (2020) · Blood · doi:10.1182/blood.2020008974 · Cited by 3
Factor VIII products: key aspects of development, clinical research and use (part 1)
Авдеева, Ж. И., Алексеевич, С. А., Бондарев, В. П., Mosyagin, V. D., & Меркулов, В. А. (2021) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2021-21-1-39-49 · Cited by 3
Fetal gene therapy for neurodegenerative lysosomal storage diseases
Baruteau, J., & Waddington, S. N. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12018 · Cited by 3
Rodriguez, M., Porada, C. D., & Almeida-Porada, G. D. (2019) · Current Stem Cell Reports · doi:10.1007/s40778-019-00165-y · Cited by 3
Genetic testing and counselling
Liang, R. H. S. (2018) · Hong Kong Medical Journal · doi:10.12809/hkmj185081 · Cited by 3
Dasgupta, I., & Keeler, A. M. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29199.ida · Cited by 3
My Pathway to Adeno-Associated Virus and Adeno-Associated Virus Gene Therapy: A Personal Perspective
Carter, B. J. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.29120.bca · Cited by 2
Bădulescu, O. V., Sîrbu, P. D., Ciocoiu, M., Vladeanu, M. C., Pleșoianu, C. E., Bojan, A., Iliescu-Halițchi, D., Tudor, R. C., Huzum, B., Sîrbu, M. T., et al. (2025) · Medicina · doi:10.3390/medicina61040570 · Cited by 2
Artemyev, V., Paremskaia, A. I., Dzhioeva, A. A., Mishina, D., Bogdanov, V. P., Krupinova, J. A., Mazloum, A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2025) · Cells · doi:10.3390/cells15010014 · Cited by 3
Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis
Mendes, A. C. S., Camelo, R. M., Henriques, L. C. M., de Almeida, D. L., de Jesus, V. E. A., Muniz, R. L., & Álvares-Teodoro, J. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2634281 · Cited by 2
Maurizi, N., Ammirati, E., Silver, E., Hong, K. N., Bui, Q. M., Argirò, A., Olivotto, I., & Adler, E. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013771 · Cited by 2
Peyvandi, F., Garagiola, I., Novembrino, C., Schiavone, L., Boscolo‐Anzoletti, M., Ciavarella, A., & Mura, V. L. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.04.017 · Cited by 2
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 3
Gene therapy and editing in the treatment of hereditary blood disorders: Medical and ethical aspects
Alburquerque, P. C., Gómez‐Tatay, L., & Aznar, J. (2021) · Clinical Ethics · doi:10.1177/14777509211057255 · Cited by 2
Mao, J., Wang, Y., Zhang, W., Shen, Y., Zhang, G., Xi, W., Wang, Q., Ruan, Z., Wang, J., & Xi, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0844-7 · Cited by 2
Cardiac Targeted Adeno-Associated Virus Injection in Rats
Katz, M. G., Hadas, Y., Vincek, A. S., Shtraizent, N., Schadt, E., & Eliyahu, E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2707-5_10 · Cited by 2
Current status of hemophilia gene therapy
Kashiwakura, Y. (2024) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.35.60 · Cited by 2
Holtkamp, S., Lagoda, F. R., Lister, A., Harish, P., Kleymann, U., Pesch, T., Soon, C. F., Pirmohamed, M., Naisbitt, D. J., & Trautwein, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450524 · Cited by 2
Tang, X., Wang, H., Yin, Y., & Zhong, G. (2025) · Gene Therapy · doi:10.1038/s41434-025-00519-8 · Cited by 2
Cellules humaines à usage thérapeutique : état de la question
Guilhot, F. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.07.051 · Cited by 3
Benyahia, B., Brumano, L. P., Pessoa, A., & da Silva, F. V. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-444-64301-8.00002-0 · Cited by 2
Enhancing hemophilia A gene therapy by strategic F8 deletions in AAV vectors
Zhao, J.-J., Tian, S.-N., Li, X., Peng, Z.-Y., Li, G., Zhang, F., Zhao, M., Zhang, J., & Zhang, X. (2025) · Blood Science · doi:10.1097/bs9.0000000000000217 · Cited by 3
The Application of DNA Viruses to Biotechnology
Schieferecke, A. J., Ralph, N. K., & Schaffer, D. V. (2025) · Viruses · doi:10.3390/v17030414 · Cited by 2
Levy‐Mendelovich, S., Walsh, C., Schapiro, J., Soffer, S., Klang, E., & Kenet, G. (2023) · Haemophilia · doi:10.1111/hae.14780 · Cited by 2
The inborn errors of metabolism: General aspects
Cox, T. M., & Watts, R. W. E. (2020) · doi:10.1093/med/9780198746690.003.0225 · Cited by 2
Terapia genowa hemofilii – czy wkrótce będzie możliwe wyleczenie?
Kaczmarek, R. (2018) · Postępy Biochemii · doi:10.18388/pb.2018_145 · Cited by 2
Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?
Anguela, X. M., & High, K. A. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12190 · Cited by 2
Christensen, I. V., Loftager, M., Rode, F., Nielsen, H. M., Kreilgaard, M., & Larsen, M. S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14441 · Cited by 2
Sun, J., Chen, X., Chai, Z., Niu, H., Dobbins, A. L., Nichols, T. C., & Li, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.880763 · Cited by 3
Nucleic acid based therapies: developing frontier for precision medicine
Pirmohamed, M. (2018) · BMJ · doi:10.1136/bmj.k223 · Cited by 2
Fetal Treatment of Genetic Disorders
Nguyen, Q.-H. L., Witt, R. G., & MacKenzie, T. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53094-1.00016-3 · Cited by 2
Levien, T. L., & Baker, D. E. (2024) · Hospital Pharmacy · doi:10.1177/00185787231222506 · Cited by 1
The Last 50 years of Hemophilia Care: A Golden Era
Seth, T. (2024) · Indian Pediatrics · doi:10.1007/s13312-024-3140-1 · Cited by 1
Gene therapy for hemophilia: Recent developments and challenges (Review)
Abdulnabi, M. A., Al‐Saadi, E. A. K. D., & Al‐Bayaa, I. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.329 · Cited by 1
Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy
Yang, Y., Chen, R., Bao, Y., Han, H., Ma, K., Pei, X., Zhang, L., & Shao, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117332 · Cited by 1
Wu, Z., Liu, H., & Wu, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-03158-6 · Cited by 1
Trevisan, B., Rodriguez, M., Ramamurthy, R. M., George, S. K., Babatunde, O. O., Dizon, J., Shields, J. E., Lankford, S. S., Schwahn, D. J., Gautreaux, M. D., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1716950 · Cited by 1
Adeno-associated viral vector gene therapy for canine hemophilia
Crudele, J. M., Doshi, B. S., & Callan, M. B. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.66 · Cited by 1
Personalized treatment for haemophilia
Dargaud, Y. G. (2020) · Hématologie · doi:10.1684/hma.2020.1567 · Cited by 1
Vishnu, P., & Aboulafia, D. M. (2025) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2025.07.010 · Cited by 1
Hemophilia: changes and new achievements in management and care
Linari, S., & Castaman, G. (2025) · International Journal of Bone Fragility · doi:10.57582/ijbf.250502.066 · Cited by 1
Sweileh, M. W. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03957-0 · Cited by 1
Saxena, H., Domenis, R., Romano, G., Biasizzo, J., Ferro, M., Ferino, D., Vicidomini, A., Iaconcig, A., Bortolussi, G., Zentilin, L., et al. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70188 · Cited by 1
Turning the corner from observation to intervention in human genetics
Nelson, D. L. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2018.01.004 · Cited by 1
An Industry update: What is the Latest News in the Therapeutic Delivery field?
Reis, C. P. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0003 · Cited by 1
Alloantibodies and Congenital Bleeding Disorders: New Insights in the Pathogenesis and Management
Tagliaferri, A., Santoro, C., Franchini, M., & Coppola, A. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1666824 · Cited by 1
Meeting Summary: ESGCT 2022 AAV Safety Plenary Session
Gallagher, T. F. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29230.tga · Cited by 1
The role of microRNAs in defining LSECs cellular identity and in regulating F8 gene expression
Jamil, M. A., Al-Rifai, R., Nüsgen, N., Altmüller, J., Oldenburg, J., & El‐Maarri, O. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1302685 · Cited by 1
Platton, S., Raheja, P., Dale, C., Guy, S., Yartey, N., & Bowyer, A. E. (2024) · Haemophilia · doi:10.1111/hae.15064 · Cited by 1
Lengler, J., Weiller, M., Horling, F., Mayrhofer, J., Schuster, M., Falkner, F. G., Gil-Fariña, I., Klugmann, M., Scheiflinger, F., Hoellriegl, W., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101424 · Cited by 1
Intrauterine Fetal Therapy: Past, Current, and Future
Kamel, R. M. A., Soliman, M. M. H., Bagunaid, M. A., Radwan, M. A., Moallem, A. A., Borah, M., & Al-Murad, B. M. (2025) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2025.153030 · Cited by 1
Recent progress in gene therapies for mucopolysaccharidoses
Ginocchio, V. M., & Brunetti‐Pierri, N. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1529564 · Cited by 1
Mao, J. H., Shen, Y., Wang, Q., Wang, Y., Ruan, Z., & Xi, X. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.01.007 · Cited by 1
[Recent advances in therapies for haemophilia].
Sun, B., & Yang, R. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.10.018 · Cited by 1
Nonsevere hemophilia A: often overlooked, but not forgotten
Lim, M. Y., & Buckner, T. W. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000600 · Cited by 1
State of the art on clinical trials of gene therapy in haemophilia
Garagiola, I., & Peyvandi, F. (2020) · doi:10.36118/pharmadvances.03.2020.05 · Cited by 1
Genetik menschlicher Erkrankungen
Graw, J. (2020) · Springer eBooks · doi:10.1007/978-3-662-60909-5_13 · Cited by 1
Hemophilia and its considerations in the dental practice
Rojas, M. C. E., Garza, H. V., Lozano, A. S., Gutiérrez, R. G. C., Quintana, G. M., Nájera, R. I. S., Regalado, S. E. F., & Soto, J. M. S. (2022) · International Journal of Applied Dental Sciences · doi:10.22271/oral.2022.v8.i1b.1408 · Cited by 1
Hematopoietic stem cell transplantation and cellular therapy
Abdel‐Azim, H., & Pulsipher, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821671-2.00003-9 · Cited by 1
Metadata
- Authors
- Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., & Pasi, K. J.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-28
- Volume
- 377
- Issue
- 26
- Pages
- 2519-2530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2775538622
- Cited by
- 694
- References
- 29
- Citations by year
- 2026: 33 · 2025: 59 · 2024: 65 · 2023: 57 · 2022: 95 · 2021: 81 · 2020: 112 · 2019: 90 · 2018: 95 · 2017: 5
- FWCI
- 63.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- University Hospitals Birmingham NHS Foundation Trust
- National Institute for Health and Care Research
- University of Cambridge
- Imperial College London
- Imperial College Healthcare NHS Trust
- Barts Health NHS Trust
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, gene therapy, factor VIII, B-domain-deleted factor VIII, codon optimization, annualized bleeding rate, factor VIII activity, dose escalation, alanine aminotransferase elevation, chronic arthropathy, neutralizing antibodies
- MeSH terms
- Dependovirus, Adult, Antibodies, Viral, DNA, Viral, Factor VIII, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Genetic Therapy, Virus Shedding, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
